{"analyses":[{"ciLowerLimit":"0.543","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.768","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","pValueComment":"Nominal P-value is 0.0142 at interim analysis based on group sequential design.","paramType":"Hazard Ratio (HR)","paramValue":"0.646","statisticalComment":"This was a stratified analysis.","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"430.0","upperLimit":"470.0","value":"450.0"},{"groupId":"OG001","lowerLimit":"310.0","upperLimit":"366.0","value":"332.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"797"},{"groupId":"OG001","value":"398"}],"units":"Participants"}],"description":"Overall survival is defined as the time interval from the date of randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Abiraterone acetate plus prednisone/prednisolone administered as four 250 mg tablets of abiraterone acetate once daily plus 5 mg prednisone/5 mg prednisolone twice daily until disease progression.","id":"OG000","title":"Abiraterone Acetate"},{"description":"Placebo plus prednisone/prednisolone administered as four placebo tablets once daily plus 5 mg prednisone/5 mg prednisolone tablet twice daily until disease progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the Intent-to-Treat (ITT) population. The ITT population is composed of all patients randomized into the study and who will be classified according to their assigned teatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 60 months","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Days"}